Elsevier

Neuropeptides

Volume 47, Issue 6, December 2013, Pages 467-475
Neuropeptides

Neuropeptides in epilepsy

https://doi.org/10.1016/j.npep.2013.10.015Get rights and content

Abstract

Neuropeptides play an important role in modulating seizures and epilepsy. Unlike neurotransmitters which operate on a millisecond time-scale, neuropeptides have longer half lives; this leads to modulation of neuronal and network activity over prolonged periods, so contributing to setting the seizure threshold. Most neuropeptides are stored in large dense vesicles and co-localize with inhibitory interneurons. They are released upon high frequency stimulation making them attractive targets for modulation of seizures, during which high frequency discharges occur. Numerous neuropeptides have been implicated in epilepsy; one, ACTH, is already used in clinical practice to suppress seizures. Here, we concentrate on neuropeptides that have a direct effect on seizures, and for which therapeutic interventions are being developed. We have thus reviewed the abundant reports that support a role for neuropeptide Y (NPY), galanin, ghrelin, somatostatin and dynorphin in suppressing seizures and epileptogenesis, and for tachykinins having pro-epileptic effects. Most in vitro and in vivo studies are performed in hippocampal tissue in which receptor expression is usually high, making translation to other brain areas less clear. We highlight recent therapeutic strategies to treat epilepsy with neuropeptides, which are based on viral vector technology, and outline how such interventions need to be refined in order to address human disease.

Introduction

Epilepsy is one of the commonest chronic brain diseases, affecting over 50 million people worldwide. It is characterised by recurrent, unprovoked seizures. The number of drugs marketed to treat epilepsy has been rapidly growing with most antiepileptic drugs targeting either sodium channels or GABA receptors. Unfortunately, despite the burgeoning of new antiepileptic drugs, one third of patients with epilepsy continues to have seizures and their epilepsies are resistant to all current available treatments (Duncan et al., 2006). In addition, the classic antiepileptic drugs which typically target ion channels or ionotropic receptors have substantial side effects which are causally linked to their mechanism of action. Neuromodulators have been explored as potential alternatives to classic antiepileptic drugs (Casillas-Espinosa et al., 2012). Unlike classical neurotransmitters, neuromodulators act through indirect modulation of neurotransmitter release or ion channel/receptor function. Their physiological function is believed to be fine-tuning of neurotransmission, thereby controlling the balance between excitation and inhibition in the CNS (Baraban and Tallent, 2004). Some of the neuromodulators, such as neuropeptide Y, share similarities in molecular structure with hormones regulating feeding (Kageyama et al., 2012). It is therefore unsurprising that whereas classical neurotransmitters operate on a millisecond scale, neuropeptides usually act over periods that are orders of magnitude longer. Neuropeptides are stored in large dense vesicles in interneurons and are released upon high frequency firing. Neuropeptides exert both pre- and postsynaptic actions on excitatory and inhibitory transmission (Baraban and Tallent, 2004). A long list of neuropeptides has been explored for the treatment of epilepsy. Of those the most promising candidates with multiple reports corroborating their direct antiepileptic and antiepileptogenic action include neuropeptide Y (NPY), galanin, dynorphin, somatostatin and ghrelin. In contrast, substance P and the tachykinens seem to have a pro-epileptic effect. These are all small peptides with several aminoacids which lack a complex protein structure (Table 1). Most of the neuropeptides act at G-protein coupled receptors thereby modulating release of neurotransmitters or modifying effects of postsynaptic receptor activation. Receptor distribution of the peptidic neuromodulators within the brain varies; however, unsurprisingly, given their importance in also regulating feeding behavior, most of the peptidic neuromodulators show high expression within the hypothalamus and hippocampal structures (Allen et al., 1983, Mitsukawa et al., 2008). Limbic, archecortical, structures have a strong impact on feeding regulation (Mogenson et al., 1980). The distribution of their target receptors renders the neuromodulators an attractive target for the treatment of epilepsy. Hippocampal sclerosis and limbic structure dysfunction is one of the most common pathologies underlying pharmacoresistant epilepsy and therefore constitutes the largest cohort in surgical series (de Tisi et al., 2011). In addition, epilepsy in patients with hippocampal sclerosis is more likely to be pharmacoresistant than epilepsy due to other lesions within the brain (Stephen et al., 2001).

Neuromodulation to treat epilepsy harbours great translational potential as neuropeptide structure, such as the structure of NPY, is highly conserved among species (Larhammar, 1996). Moreover, as endogenous substances, neuropeptides are less likely substrates of multi drug transporters. Multi drug transporters are abundantly expressed at the blood brain barrier and can prevent drugs from reaching sufficient concentrations within the brain parenchyma, thereby contributing to pharmacoresistant epilepsy (Lazarowski et al., 2007).

One pharmacokinetic difficulty that needs to be overcome is the poor bioavailability of neuropeptides, which are prone to cleavage by peptidases and show poor blood brain barrier penetration. This can be overcome by non-peptide analogues such as galnon, a synthetic galanin receptor agonist (Saar et al., 2002). An alternative to this approach is local neuromodulator delivery. This can be achieved via polymers or with viral vector based technologies which are increasingly recognized as a technique that has translational potential in treating pharmacoresistant epilepsy (Szybala et al., 2009, Wykes et al., 2012).

Numerous neuropetides have been proposed to have direct and indirect effects on epilepsy and seizures. One, ACTH, has a long history of use in childhood epilepsies, in particular West syndrome, although its mode of action in epilepsy is unclear. We have concentrated on the direct antiepileptogenic and anticonvulsive effect of NPY, galanin, somatostatin, dynorphin and ghrelin, and the pro-epileptic effects of substance P. We will review their mechanism of action and receptor function with regards to their effects on epilepsy. Finally, we will highlight the translational research that has been done in the past few years aimed at treating seizures with neuropeptide delivery focussing on reports of viral vector mediated delivery of neuropeptides.

Section snippets

Npy

NPY is probably the most studied neuropeptide in epilepsy. NPY is structurally related to two gut peptides, peptideYY and pancreatic polypeptide (Tatemoto, 1982, Tatemoto et al., 1982) and similarly plays a pivotal role in regulating food intake (Chee and Colmers, 2008, Kageyama et al., 2012). Since its discovery, the range of functions identified for NPY has expanded considerably. NPY’s effects on the brain include regulation of anxiety, pain, depression, drug addiction and regulation of

Galanin

Galanin is a small peptide containing 29 amino acids, which was first isolated in porcrine intestine (Tatemoto et al., 1983). The first compelling observations pointing to a role of galanin in epilepsy were made in animal models of status epilepticus. Mazarati and colleagues found that rats subjected to continuous seizure activity such as is seen in sustained status epilepticus (SSSE) exhibit profound and prolonged galanin depletion within the hippocampus for at least a week after SSSE (

Ghrelin

Ghrelin, a growth-hormone secretagogue (GHS), was isolated from rodent stomach in (Kojima et al., 1999). Growth-hormone secretagogues (GHSs) are molecules which stimulate the release of growth hormone (GH) from the pituitary. Ghrelin stimulates the release of GH from the pituitary, which is one of its main functions. In the recent years, the spectrum of ghrelins function has been expanded to include sleep regulation, cardiovascular regulation and anticonvulsant properties (Portelli et al., 2012

Somatostatin

Somatostatin is a small neuropeptide, also called growth hormone-inhibiting hormone (GHIH), which is expressed in the hypothalamus in the periventricular nucleus along with its main functions which is regulation of the endocrine system, mainly inhibition of growth hormone release. Apart from the hypothalamus, somatostatin is abundantly expressed in the brain in the amygdala, hippocampus, striatum, cerebral cortex, olfactory regions, and the brainstem (Viollet et al., 2008). To date five

Dynorphin

Dynorphin, a tridecapeptide which acts at opioid receptors, was first characterized in 1979 (Goldstein et al., 1979, Schwarzer, 2009). Dynorphin is a ligand of the opioid receptors (delta, mu and kappa) with the kappa receptor mediating many of dynorphin’s effects (Chavkin et al., 1982). However, dynorpin and prodynorphin-derived peptides also modulate NMDA receptor signaling in a receptor independent manner thus reducing NMDA receptor activity (Kanemitsu et al., 2003, Kuzmin et al., 2006, Oz

Substance P

Substance P is an 11 aminoacid long peptide which is a member of the tachykinin family (Table 1). This peptide was intensively investigated with regards to pain and nociception (Vaught, 1988). However, subsequently a role for substance P in CNS disorders such as psychiatric disorders has been elucidated (Kramer et al., 1998). Substance P acts at the neurokinin 1 (NK1) receptor, which is a G-protein coupled receptor. Binding of substance P at the NK1 receptor evokes a depolarization of the cell

Conclusion

NPY, galanin, ghrelin, somatostatin and dynorphin are promising candidates for future treatment trials targeting pharmacoresistant seizures in patients. Their pharmacodynamic properties make them attractive targets for future research into treatment of human epilepsies. However, the pharmacokinetic profile of these neuropeptidic modulators requires local delivery techniques. Recent studies used adenoassociated viral (AAV) delivery techniques, which have emerged as promising techniques for local

Acknowledgments

This work was undertaken at University of College London (UCL) and was partly funded by the Department of Health National Institute for Health Research Biomedical Research Centres funding scheme and Epilepsy Research UK.

References (138)

  • J. De Tisi et al.

    The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study

    Lancet

    (2011)
  • M. Decressac et al.

    Neuropeptide Y and its role in CNS disease and repair

    Exp. Neurol.

    (2012)
  • M. Decressac et al.

    Neuropeptide Y stimulates proliferation, migration and differentiation of neural precursors from the subventricular zone in adult mice

    Neurobiol. Dis.

    (2009)
  • M. Decressac et al.

    Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington’s disease

    Exp. Neurol.

    (2010)
  • J.S. Duncan et al.

    Adult epilepsy

    Lancet

    (2006)
  • C.R. Gøtzsche et al.

    Combined gene overexpression of neuropeptide Y and its receptor Y5 in the hippocampus suppresses seizures

    Neurobiol Dis.

    (2012)
  • J.G. Hohmann et al.

    Distribution and regulation of galanin receptor 1 messenger RNA in the forebrain of wild type and galanin-transgenic mice

    Neuroscience

    (2003)
  • O.W. Howell et al.

    Neuropeptide Y is important for basal and seizure-induced precursor cell proliferation in the hippocampus

    Neurobiol. Dis.

    (2007)
  • D. Hoyer et al.

    Classification and nomenclature of somatostatin receptors

    Trends Pharmacol. Sci.

    (1995)
  • Y.L. Hurd et al.

    The human neostriatum shows compartmentalization of neuropeptide gene expression in dorsal and ventral regions: an in situ hybridization histochemical analysis

    Neuroscience

    (1995)
  • A.S. Jacoby et al.

    Critical role for GALR1 galanin receptor in galanin regulation of neuroendocrine function and seizure activity

    Brain Res. Mol. Brain Res.

    (2002)
  • H. Kageyama et al.

    Neuronal circuits involving neuropeptide Y in hypothalamic arcuate nucleus-mediated feeding regulation

    Neuropeptides

    (2012)
  • Y. Kanemitsu et al.

    Dynorphin A inhibits NMDA receptors through a pH-dependent mechanism

    Mol. Cell. Neurosci.

    (2003)
  • I. Kanter-Schlifke et al.

    Galanin gene transfer curtails generalized seizures in kindled rats without altering hippocampal synaptic plasticity

    Neuroscience

    (2007)
  • K. Klemp et al.

    Repeated inhibitory effects of NPY on hippocampal CA3 seizures and wet dog shakes

    Peptides

    (2001)
  • N. Kofler et al.

    Altered expression of NPY-Y1 receptors in kainic acid induced epilepsy in rats

    Neurosci. Lett.

    (1997)
  • S. Kovac et al.

    In vitro effects of neuropeptide Y in rat neocortical and hippocampal tissue

    Neurosci. Lett.

    (2011)
  • M. Kozhemyakin et al.

    Somatostatin type-2 receptor activation inhibits glutamate release and prevents status epilepticus

    Neurobiol. Dis.

    (2013)
  • R. Lang et al.

    The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease

    Pharmacol. Ther.

    (2007)
  • D. Larhammar

    Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide

    Regul. Pept.

    (1996)
  • A.M. Mazarati

    Galanin and galanin receptors in epilepsy

    Neuropeptides

    (2004)
  • A.M. Mazarati et al.

    Effects of somatostatin and anti-somatostatin serum on picrotoxin-kindled seizures

    Neuropharmacology

    (1992)
  • A.M. Mazarati et al.

    Anticonvulsant effects of four neuropeptides in the rat hippocampus during self-sustaining status epilepticus

    Neurosci. Lett.

    (2002)
  • A. Mazarati et al.

    Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice

    Neuroscience

    (2004)
  • C.D. McColl et al.

    Galanin receptor-1 knockout mice exhibit spontaneous epilepsy, abnormal EEGs and altered inhibition in the hippocampus

    Neuropharmacology

    (2006)
  • T.J. McCown

    Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo

    Mol. Ther.

    (2006)
  • F. Mennicken et al.

    Restricted distribution of galanin receptor 3 (GalR3) mRNA in the adult rat central nervous system

    J. Chem. Neuroanat.

    (2002)
  • G.J. Mogenson et al.

    From motivation to action: Functional interface between the limbic system and the motor system

    Prog. Neurobiol.

    (1980)
  • B.D. Obay et al.

    Antiepileptic effects of ghrelin on pentylenetetrazole-induced seizures in rats

    Peptides

    (2007)
  • B.D. Obay et al.

    Dose dependent effects of ghrelin on pentylenetetrazole-induced oxidative stress in a rat seizure model

    Peptides

    (2008)
  • S. Reibel et al.

    Neuropeptide Y and epilepsy: varying effects according to seizure type and receptor activation

    Peptides

    (2001)
  • Y.S. Allen et al.

    Neuropeptide Y distribution in the rat brain

    Science

    (1983)
  • S.G. Barreto et al.

    Galanin receptor 3 – a potential target for acute pancreatitis therapy

    Neurogastroenterol. Motil.

    (2011)
  • T. Bartfai et al.

    Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests

    Proc. Natl. Acad. Sci. USA

    (2004)
  • E.E. Benarroch

    Neuropeptide Y: its multiple effects in the CNS and potential clinical significance

    Neurology

    (2009)
  • S. Boehm et al.

    Somatostatin inhibits excitatory transmission at rat hippocampal synapses via presynaptic receptors

    J. Neurosci.

    (1997)
  • T. Branchek et al.

    Molecular biology and pharmacology of galanin receptors

    Ann. N. Y. Acad. Sci.

    (1998)
  • T.C. Burazin et al.

    Galanin-R1 and -R2 receptor mRNA expression during the development of rat brain suggests differential subtype involvement in synaptic transmission and plasticity

    Eur. J. Neurosci.

    (2000)
  • J.P. Camiña

    Cell biology of the ghrelin receptor

    J. Neuroendocrinol.

    (2006)
  • P.M. Casillas-Espinosa et al.

    Regulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsy

    Epilepsia

    (2012)
  • Cited by (90)

    View all citing articles on Scopus
    View full text